Behandlung von ESBL-Infektionen MERINO Trial: Ist Piperacillin/Tazobactam bei schweren ESBL-Infektionen sicher? Effect of piperacillin-tazobactam vs meropenem on 30-day mortality for patients with e coli or klebsiella pneumoniae bloodstream infection and...
More
Behandlung von ESBL-Infektionen MERINO Trial: Ist Piperacillin/Tazobactam bei schweren ESBL-Infektionen sicher? Effect of piperacillin-tazobactam vs meropenem on 30-day mortality for patients with e coli or klebsiella pneumoniae bloodstream infection and ceftriaxone resistance: A randomized clinical trial. Harris PNA, Tambyah PA, Lye DC, Mo Y, Lee TH, Yilmaz M, Alenazi TH, Arabi Y, Falcone M, et al. JAMA 2018; 320:984-994 IMPORTANCE: Extended-spectrum ß-lactamases mediate resist- minimum of 4 days, up to a maximum of 14 days, with the total dura- ance to third-generation cephalosporins (eg, ceftriaxone) in Escheri- tion determined by the treating clinician. chia coli and Klebsiella pneumoniae. Significant infections caused MAIN OUTCOMES AND MEASURES: The primary outcome was by these strains are usually treated with carbapenems, potentially all-cause mortality at 30 days after randomization. A noninferiority selecting for carbapenem resistance. Piperacillin-tazobactam may be marg
Less
